<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616967</url>
  </required_header>
  <id_info>
    <org_study_id>JHOC-J0785, CDR0000586335</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-SKCCC-J0785</secondary_id>
    <secondary_id>NA_00012756</secondary_id>
    <nct_id>NCT00616967</nct_id>
  </id_info>
  <brief_title>Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer</brief_title>
  <official_title>A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and Nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in HER2-negative Primary Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized
      nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by
      killing the cells or by stopping them from dividing. Vorinostat may stop the growth of tumor
      cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help
      carboplatin and paclitaxel albumin-stabilized nanoparticle formulation work better by making
      tumor cells more sensitive to the drugs. Giving chemotherapy with or without vorinostat
      before surgery may make the tumor smaller and reduce the amount of normal tissue that needs
      to be removed.

      PURPOSE: This randomized phase II trial is studying how well giving carboplatin together with
      paclitaxel albumin-stabilized nanoparticle formulation works with or without vorinostat in
      treating women with breast cancer that can be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine pathological complete response (pCR) rates in patients with HER2-negative
           primary operable breast cancer treated with neoadjuvant therapy comprising carboplatin
           and paclitaxel albumin-stabilized nanoparticle formulation (CP) with vs without
           vorinostat.

      Secondary

        -  To evaluate the safety of these regimens in these patients.

        -  To estimate clinical complete response (cCR) rates in patients treated with these
           regimens.

        -  To correlate baseline and change (day 15) in surrogate uptake values (SUV) on FDG-PET
           with pathological and clinical response in patients treated with these regimens, and to
           determine what percent of women with ≥ 25% or ≥ 50% reduction in SUV on day 15 achieve a
           pCR and a cCR to CP with vs without vorinostat.

        -  To correlate baseline and change in markers of proliferation with pathological and
           clinical response in patients treated with these regimens.

        -  To evaluate long term outcomes (e.g., recurrence of the breast cancer, development of a
           new cancer, or death) for patients treated with these regimens.

      Tertiary

        -  To evaluate baseline and change in candidate gene methylation and expression profiles.

        -  To evaluate baseline and change in tissue and peripheral blood mononuclear cell histone
           acetylation.

        -  To compare cCR and pCR in women with basal-like features versus other subtypes.

      OUTLINE: This is a multicenter, randomized, double-blind, phase II study (primary study
      portion) with a 6-12 patient run-in portion.

        -  Run-in portion: Patients receive carboplatin IV and paclitaxel albumin-stabilized
           nanoparticle formulation IV on day 1 and oral vorinostat on days 1-3. Treatment repeats
           weekly for 12 weeks in the absence of disease progression or unacceptable toxicity. Once
           safety of the combination of chemotherapy and vorinostat is confirmed, subsequently
           enrolled patients are entered to the primary study portion.

        -  Primary study portion: Patients are stratified by hormone receptor status (estrogen
           receptor [ER]-negative and progesterone receptor [PR]-negative vs ER-positive and/or
           PR-positive). Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive carboplatin IV and paclitaxel albumin-stabilized
                nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment
                repeats weekly for 12 weeks in the absence of disease progression or unacceptable
                toxicity.

             -  Arm II: Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle
                formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly
                for 12 weeks in the absence of disease progression or unacceptable toxicity.

      Within 2-4 weeks after completion of neoadjuvant chemotherapy, patients undergo breast
      conserving surgery or mastectomy at the discretion of the treating physician.

      Patients undergo tumor tissue biopsy at baseline, day 15, and at the time of definitive
      surgery. Samples are analyzed by immunohistochemistry (IHC), RNA extraction, and gene
      expression analysis using RT-PCR to identify candidate markers for response and molecular
      profiles that may be relevant to an understanding of drug mechanisms. Methylation of relevant
      genes (e.g., ERalpha, APC-1, RARbeta, cyclin D2, Twist, RASSF1A, and HIN-1) are evaluated by
      quantitative multiplex methylation-specific PCR. Changes in gene expression as a result of
      treatment are determined by IHC or quantitative RT-PCR. Blood samples are collected at
      baseline, day 15, at the time of definitive surgery, and 4 weeks after surgery for DNA
      methylation studies, pharmacogenomic studies, and histone acetylation assays. Patients also
      undergo fludeoxyglucose F 18-positron emission tomography (FDG-PET) or PET/CT at baseline and
      day 15 to assess treatment response as measured by standardized uptake values.

      After completion of study treatment, patients are followed every 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR) Rate</measure>
    <time_frame>Time of breast cancer surgery</time_frame>
    <description>The primary end point was pCR, defined as no viable invasive cancer in breast and axilla. All other cases were defined as non-pCR. The pCR rate was determined in each arm separately by performing an intent-to-treat (ITT) analysis of all randomized patients. Patients with unknown pCR status were considered non-responders. Computation of associated 90% confidence intervals did not account for the sequential design.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as Measured by NCI CTCAE Version 3.0</measure>
    <time_frame>Active treatment until 30 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Complete Response (cCR) Rate</measure>
    <time_frame>Time of breast cancer surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Uptake Values as Measured by Baseline and Changes (Day 15) on FDG-PET</measure>
    <time_frame>Baseline and day 15</time_frame>
    <description>The standard uptake value used for the PET analysis was SULmax, which is the standard uptake value normalized for lean body mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Change in Markers of Apoptosis and Proliferation</measure>
    <time_frame>Time of breast cancer surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Term Outcomes</measure>
    <time_frame>Indefinite survival analysis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Change in Continuous Variables (e.g., Candidate Gene Methylation, Expression Profiles, Tissue, and Peripheral Blood Mononuclear Cell Histone Acetylation)</measure>
    <time_frame>Time of breast cancer surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Abraxane, nab-Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed infiltrating ductal breast cancer by core needle biopsy

               -  Mixed ductal and lobular disease allowed

               -  Infiltrating lobular cancer allowed in the run-in portion only

          -  Unresected, clinically measurable disease, meeting 1 of the following clinical staging
             criteria:

               -  T2, T3, or T4 lesion, any N, M0

               -  T1c, N1-3,M0

          -  Patients with skin metastases to the ipsilateral breast for whom chemotherapy is
             planned prior to definitive surgery are eligible for the primary study portion

          -  HER2-negative disease

          -  Hormone receptor status* meeting 1 of the following criteria:

               -  Estrogen receptor (ER)-negative and progesterone receptor (PR)-negative

               -  ER-positive (grade II or III) and PR-positive or PR-negative NOTE: *Any ER or PR
                  status for the run-in portion

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Menopausal status not specified

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 150,000/mm³

          -  Hemoglobin ≥ 9 g/dL

          -  Creatinine ≤ 1.5 times the upper limit of normal (ULN)

          -  Creatinine clearance ≥ 50 mL/min

          -  Total bilirubin normal

          -  AST(SGOT) and ALT(SGPT) ≤ 2.5 times (ULN)

          -  alkaline phosphatase ≤ 2.5 times ULN

          -  PT such that INR ≤ 1.5 (or an in-range INR, usually between 2 and 3, if a patient is
             on a stable dose of therapeutic warfarin) and PTT ≤ ULN

          -  Adequate cardiac function defined as no evidence of PR prolongation or AV block on
             baseline electrocardiogram (ECG)

          -  Willing to use effective, non-hormonal contraception while on treatment and for at
             least 3 months thereafter

          -  Not pregnant or nursing

          -  No pre-existing peripheral neuropathy ≥ grade 2

          -  No history of severe hypersensitivity reaction to any drug formulated with polysorbate
             80 or to E. coli-derived products

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to vorinostat

          -  No medical condition which, in the opinion of the investigator, puts the patient at
             risk of potentially serious complications while on this therapy

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior valproic acid or other histone deacetylase inhibitor

          -  No prior chemotherapy, radiotherapy, or endocrine therapy for this cancer

               -  Prior tamoxifen or raloxifene or another agent for prevention of breast cancer
                  allowed as long as the patient has discontinued the treatment ≥ 1 month prior to
                  baseline study biopsy

          -  No systemic treatment for prior cancer within the past 5 years (primary study portion)

          -  No prior or ongoing systemic treatment for this cancer (primary study portion)

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent histone deacetylase inhibitor

          -  No other concurrent chemotherapy, antiestrogen therapy, radiotherapy, or other
             investigational systemic therapy

          -  No other concurrent biologic therapy

          -  No other concurrent investigational drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vered Stearns, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Purdue University of Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Health System</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <results_first_submitted>April 8, 2014</results_first_submitted>
  <results_first_submitted_qc>June 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2014</results_first_posted>
  <last_update_submitted>June 16, 2014</last_update_submitted>
  <last_update_submitted_qc>June 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>ductal breast carcinoma</keyword>
  <keyword>lobular breast carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Run-in Phase (Arm 0)</title>
          <description>Phase 0 - To confirm safety and dosing prior to moving to randomized phase 2 portion (Arms 1 and 2).
Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
vorinostat: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Arm I)</title>
          <description>Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
placebo: Given orally</description>
        </group>
        <group group_id="P3">
          <title>Vorinostat (Arm II)</title>
          <description>Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
vorinostat: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The information for the primary populations for analysis are included (Placebo and Vorinostat arms). The initial &quot;run-in phase&quot; of 6 participants was conducted to confirm safety and dosing for the combination of vorinostat with chemotherapy only, and these data are not a part of our primary study analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Arm 1)</title>
          <description>Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
placebo: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Vorinostat (Arm 2)</title>
          <description>Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
vorinostat: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="24" upper_limit="72"/>
                    <measurement group_id="B2" value="48" lower_limit="31" upper_limit="68"/>
                    <measurement group_id="B3" value="48" lower_limit="24" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>ECOG (Eastern Cooperative Oncology Group) criteria is a measure of patient performance status due to symptoms. A score of ECOG = 0 is defined as a person who is asymptomatic. A score of ECOG =1 is a defined as a person who has symptoms, but is fully ambulatory.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ECOG 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Size</title>
          <units>centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="1.7" upper_limit="18"/>
                    <measurement group_id="B2" value="4" lower_limit="1.5" upper_limit="11.5"/>
                    <measurement group_id="B3" value="4" lower_limit="1.5" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nodal Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Grade</title>
          <description>Tumor grade is the description of a tumor based on how abnormal the tumor cells and tissue look under a microscope. It is an indicator of how quickly a tumor is likely to grow and spread. If the cells of the tumor are close to those of normal cells, the tumor is called “well-differentiated.” Tumors that are “undifferentiated” or “poorly differentiated” have abnormal-looking cells and may lack normal tissue structures. A grade = 1 means well differentiated (low grade). A grade = 2 means moderately differentiated (intermediate grade). A grade = 3 means poorly differentiated (high grade).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Receptor Status</title>
          <description>Estrogen receptors (ER) and Progesterone receptors (PR) are found in breast cancer cells that depend on estrogen and related hormones to grow. If breast cancer cells have estrogen receptors, the cancer is called ER-positive breast cancer (ER+) . If breast cancer cells have progesterone receptors, the cancer is called PR-positive breast cancer (PR+). If the cells do not have either of these two receptors, the cancer is called ER/PR-negative (ER- and PR-).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ER-/PR-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER+/PR+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER+/PR-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER-/PR+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathological Complete Response (pCR) Rate</title>
        <description>The primary end point was pCR, defined as no viable invasive cancer in breast and axilla. All other cases were defined as non-pCR. The pCR rate was determined in each arm separately by performing an intent-to-treat (ITT) analysis of all randomized patients. Patients with unknown pCR status were considered non-responders. Computation of associated 90% confidence intervals did not account for the sequential design.</description>
        <time_frame>Time of breast cancer surgery</time_frame>
        <population>The information for the primary populations for analysis are included (Placebo and Vorinostat arms). The initial &quot;run-in phase&quot; of 6 participants was conducted to confirm safety and dosing for the combination of vorinostat with chemotherapy only, and these data are not a part of our primary study analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
vorinostat: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pathological Complete Response (pCR) Rate</title>
          <description>The primary end point was pCR, defined as no viable invasive cancer in breast and axilla. All other cases were defined as non-pCR. The pCR rate was determined in each arm separately by performing an intent-to-treat (ITT) analysis of all randomized patients. Patients with unknown pCR status were considered non-responders. Computation of associated 90% confidence intervals did not account for the sequential design.</description>
          <population>The information for the primary populations for analysis are included (Placebo and Vorinostat arms). The initial &quot;run-in phase&quot; of 6 participants was conducted to confirm safety and dosing for the combination of vorinostat with chemotherapy only, and these data are not a part of our primary study analyses.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patients were stratified by hormone receptor status and randomly assigned to either arm 1 or 2. This study was designed using Simon’s two-stage design for each arm in parallel. Interim analysis of early stopping for futility was conducted for the first 32 patients (16 patients per arm) and the study proceeded as more than 2 patients achieved a pCR in each arm (31 patients per arm). This design had 80% power to detect a 25% pCR rate versus a null rate of 10% with a type I error rate of 0.10.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pathological complete response rate</param_type>
            <param_value>0.274</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.169</ci_lower_limit>
            <ci_upper_limit>0.402</ci_upper_limit>
            <estimate_desc>The Estimation Parameter provided above is for overall pCR for both arms combined. We estimated pCR for each arm separately as well.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>pCR in placebo arm (arm 1)</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.142</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>pCR in vorinostat arm (arm 2)</param_type>
            <param_value>0.258</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.119</ci_lower_limit>
            <ci_upper_limit>0.446</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety as Measured by NCI CTCAE Version 3.0</title>
        <time_frame>Active treatment until 30 days post-treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Complete Response (cCR) Rate</title>
        <time_frame>Time of breast cancer surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standard Uptake Values as Measured by Baseline and Changes (Day 15) on FDG-PET</title>
        <description>The standard uptake value used for the PET analysis was SULmax, which is the standard uptake value normalized for lean body mass.</description>
        <time_frame>Baseline and day 15</time_frame>
        <population>Of the 17 &quot;responders&quot; from the primary outcome measure, 16 participants had PET data evaluable for analysis. Of the 45 &quot;non-responders&quot; from the primary outcome measure, 43 participants had PET data evaluable for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Responders</title>
            <description>Pooled data from participants who received a pathologic complete response across arms.</description>
          </group>
          <group group_id="O2">
            <title>Non-Responders</title>
            <description>Pooled data from participants who did not receive a pathologic complete response across arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Standard Uptake Values as Measured by Baseline and Changes (Day 15) on FDG-PET</title>
          <description>The standard uptake value used for the PET analysis was SULmax, which is the standard uptake value normalized for lean body mass.</description>
          <population>Of the 17 &quot;responders&quot; from the primary outcome measure, 16 participants had PET data evaluable for analysis. Of the 45 &quot;non-responders&quot; from the primary outcome measure, 43 participants had PET data evaluable for analysis.</population>
          <units>percentage of change in SULmax</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="4.4" upper_limit="85.3"/>
                    <measurement group_id="O2" value="32.9" lower_limit="-84.2" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The estimates provided are based upon a multivariate analysis using a logistic regression adjusting for hormone receptor status. Patients with ≥50% reduction in SULmax were more likely to achieve a pCR.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>22.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Change in Markers of Apoptosis and Proliferation</title>
        <time_frame>Time of breast cancer surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Outcomes</title>
        <time_frame>Indefinite survival analysis</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Change in Continuous Variables (e.g., Candidate Gene Methylation, Expression Profiles, Tissue, and Peripheral Blood Mononuclear Cell Histone Acetylation)</title>
        <time_frame>Time of breast cancer surgery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Run-in Phase (Arm 0)</title>
          <description>Phase 0 - To confirm safety and dosing prior to moving to randomized phase 2 portion (Arms 1 and 2).
Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
vorinostat: Given orally
Events summarized in this arm are those that met 5% reporting threshold in Arms I and II.</description>
        </group>
        <group group_id="E2">
          <title>Arm I</title>
          <description>Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
placebo: Given orally</description>
        </group>
        <group group_id="E3">
          <title>Arm II</title>
          <description>Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
vorinostat: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Amemia (hemoglobin)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutropenia (neutrophils)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="31"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia (platelets)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="31"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="31"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="31"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="31"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>Sinus infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT (elevated)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="31"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="31"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="31"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="31"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A proportion of women received additional preoperative chemotherapy after study treatment,complicating the evaluation of primary endpoint and role of FDG-PET in predicting response. Limited matched samples for Ki67 analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Vered Stearns</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>443-287-6489</phone>
      <email>vstearn1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

